SavedAdd your journal

Journals / Journal of Clinical and Experimental Investigations / 2012 / Cilt: 3 - Sayı: 1

An industrial risk: Beryllium

Endüstriyel bir risk: Berilyum

Metin AYTEKİN
Emrah ÇAYLAK
Pages
141–148
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, it is summarized the general properties of beryllium exposure, the immunopathogenesis and genetic differences of beryllium-induced diseases, genotoxicity and the carcinogenic effects of beryllium.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Beryllium is a vocational disease factor and beryllium exposure can potentially lead to Chronic Beryllium Disease (CBD) in 2-6 % of workers.
📊
Key Findings & Data:While acute lymphocytic pneumonia occurred in individuals who were exposed to high doses of beryllium, low dose exposure to beryllium followed by a long subclinical period can cause CBD characterized with chronic granulomatosis.
💡
Conclusion & Impact:In this review, it is summarized the general properties of beryllium exposure, the immunopathogenesis and genetic differences of beryllium-induced diseases, genotoxicity and the carcinogenic effects of beryllium.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Beryllium is a vocational disease factor and beryllium exposure can potentially lead to Chronic Beryllium Disease (CBD) in 2-6 % of workers. While acute lymphocytic pneumonia occurred in individuals who were exposed to high doses of beryllium, low dose exposure to beryllium followed by a long subclinical period can cause CBD characterized with chronic granulomatosis. It has been observed that varying amounts of beryllium exposure are necessary to produce symptoms of CBD or beryllium sensitization (BeS). Genetic differences between patients may be the underlying cause of these dose-effects and further study of the differences in patients exposed to beryllium may lead to earlier diagnosis and the identification of biomarkers of CBD. In this review, it is summarized the general properties of beryllium exposure, the immunopathogenesis and genetic differences of beryllium-induced diseases, genotoxicity and the carcinogenic effects of beryllium.

Özet

Berilyum mesleki bir hastalık faktörü olup, berilyum maruz kalan işçilerin % 2-16’sında Kronik Berilyum Hastalığı’na (KBH) neden olmaktadır. Yüksek dozda maruziyete bağlı olarak bireylerde akut lenfositik pnömoni; düşük dozlarda maruziyette ise uzun bir subklinik periyodu takiben kronik granulomatoz karakterli KBH görülmektedir. Farklı miktarlarda berilyum maruziyetinin KBH ve berilyum hassasiyeti (BeS) belirtilerine yol açtığı gözlenmiştir. Hastalar arasındaki genetik farklılıklar bu doz-etki ilişkisine neden olmakta, berilyuma maruz kalmış hastalardaki farklılıklar hakkında yapılacak daha fazla çalışma ise erken tanıya ve KBH belirteçlerinin belirlenmesine neden olacaktır. Bu derlemede berilyum maruziyetinin genel özellikleri, berilyumla- indüklenen hastalıkların immunopatogenezi ve genetik farklılıkları ile berilyumun genotoksisitesi ve karsinojenik etkileri özetlenmiştir.

🔖

Cite This Article

AYTEKİN, M., ÇAYLAK, E. (2022). An industrial risk: Beryllium. Journal of Clinical and Experimental Investigations, Cilt: 3 - Sayı: 1, 141–148. https://ajindex.com/articles/561940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Van Ordstarnd HS, Hughes R, Carmody MG. Chemical pneumonia in workers extracting beryllium oxide. Report of three cases. Cleve Clin Q 1984;51(2):431-9
  2. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 1946;28(2):197-211
  3. Hardy HL. Delayed chemical pneumonitis in workers exposed to beryllium compounds. Am Rev Tuberc 1948; 57(6):547-56
  4. McCanlies EC, Kreiss K, Andrew M, Weston A. HLADPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol 2003;157(5):388-98
  5. Kreiss K, Mroz MM, Newman LS, Martyny J, Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m3. Am J Ind Med 1996;30(1):16-25
  6. Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001;43(3):238-49
  7. Schuler CR, Kent MS, Deubner DC, et al. Processrelated risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med 2005;47(3):195-205
  8. Newman LS, Maier LA, Martyny JW, Mroz MM, Van- Dyke M, Sackett HM. Beryllium workers’ health risks. J Occup Environ Hyg 2005;2(6):D48-50
  9. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989;320(17):1103-9
  10. Sprince NL, Kanarek DJ, Weber AL, Chamberlin RI, Kazemi H. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis 1978;117(6):1011-7
  11. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease: Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46(4):545-61
  12. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992;145(5):1212-4
  13. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989;139(6):1479-86
  14. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001;43(3):231-7
  15. Freiman DG, Hardy HL. Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a